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Abstract
Background: Depression is prevalent in people with type 2 diabetes and affects both glycemic
control and overall quality of life. The aim of this trial was to evaluate the effect of the
antidepressant paroxetine on metabolic control, quality of life and mental well-being in mildly
depressed women with type 2 diabetes.
Methods: We randomised 15 mildly depressed women with non-optimally controlled type 2
diabetes to a 10-week single-blind treatment with either paroxetine 20 mg per day or placebo.
Primary efficacy measurements were glycemic control and quality of life. Glycosylated hemoglobin
A1c (GHbA1c) was used as a measure of glycemic control. Quality of life was evaluated using RAND-
36. Mental state was assessed using two clinician-rated scoring instruments, Hamilton's Anxiety
Scale (HAM-A) and Montgomery-Åsberg's Depression Rating Scale (MADRS), and a patient-rated
scoring instrument, Beck's Depression Inventory (BDI).
Results: At the end of the study no significant difference between groups in improvement of
quality of life was found. A trend towards a superior improvement in glycemic control was found
in the paroxetine group (p = 0.08). A superior increase in sex-hormone-binding-globuline (SHBG)
levels was evidenced in the paroxetine group (p = 0.01) as a sign of improved insulin sensitivity.
There was also a trend for superior efficacy of paroxetine in investigator-rated anxiety and
depression. This notion was supported by a trend for superior decrease of serum cortisol levels in
the paroxetine group (p = 0.06).
Conclusion: Paroxetine has a beneficial effect on measures of insulin sensitivity and may improve
glycemic control. Larger studies of longer duration are needed to verify the benefits of paroxetine
in type 2 diabetes. While waiting for more conclusive evidence it seems sensible to augment
standard care of type 2 diabetes with paroxetine even in patients who do not fulfil routine
psychiatric criteria for initiation of antidepressant drug treatment.
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Background
Type 2 diabetes, characterised by both insulin resistance
and impaired insulin secretion, is a common disease with
rapidly increasing prevalence worldwide [1,2]. Insulin
resistance is one of the primary metabolic defects, both in
the metabolic syndrome and in type 2 diabetes. Therefore
a main treatment target is to improve insulin sensitivity.
The cornerstones of treatment are exercise and improved
dietary habits. Insulin sensitivity improves with weight
loss and physical activity [3]. Unfortunately, success of
non-pharmacologic treatment is rare. Therefore other
means to increase insulin sensitivity are urgently needed.
One possibility for pharmacological treatment of insulin
resistance is the use of serotonergic agents such as the
selective serotonin reuptake inhibitors (SSRIs). It has pre-
viously been shown that the SSRI fluoxetine lowers blood
glucose levels in type 2 diabetics [4,5]. Fluoxetine has also
been shown to promote weight loss [6], which in itself
would improve insulin sensitivity. Interestingly, this effect
of fluoxetine on insulin sensitivity also occurs independ-
ently of weight loss [7].
The metabolic syndrome is characterised not only by insu-
lin resistance but also by obesity, elevated blood pressure,
dyslipidemia, an increased risk for cardiovascular disease
and for depression [8]. Symptoms of depression among
type 2 diabetics have been shown to correlate with glyc-
emic control although it is not clear whether this is due
primarily to non-compliance with the anti-diabetic medi-
cation or to depression [9]. Therefore, in order to reduce
the risk for cardiovascular diseases associated with the
metabolic syndrome and type 2 diabetes, it is important
to treat not only hyperglycemia in type 2 diabetes but also
all other risk factors accompanying the disease. It is of
interest to see whether antidepressant drugs could be ben-
eficial for diabetics with regard to metabolism as well as
mental health.
The aim of our investigator-initiated study was to assess
whether the SSRI paroxetine has beneficial effects on the
overall metabolic control in type 2 diabetics, in addition
to possible beneficial effects on mental health.
Methods
Mildly depressed type 2 diabetes patients were invited to
participate in this 10-week trial. All subjects received
standard diabetes treatment by their primary care physi-
cians prior to and during the trial. Postmenopausal
women over 50 years of age, who had been diagnosed
with type 2 diabetes at least a year prior to study entry
were eligible for the study. They had to be on stable anti-
diabetic medication for at least three months before enter-
ing the study.
All subjects were interviewed by the same investigator
(M.P.) and were evaluated using two clinician-rated eval-
uation scales, Hamilton's Anxiety Scale (HAM-A) [10] and
Montgomery-Åsberg's Depression Rating Scale (MADRS)
[11], and two patient-rated scales, Beck's Depression
Inventory [12] (BDI) and the RAND-36 for assessment of
quality of life [13].
Inclusion criteria were unsatisfactory glycemic control,
defined as GHbA1c ≥ 6.5% or fasting blood glucose ≥ 7.0
mmol/l, and mild depression, defined as a score between
2.5 and 12 on the MADRS, i.e. they had a mild to moder-
ate but not a severe depression requiring immediate
treatment.
Subjects with major complications due to diabetes (e.g.
major cardiovascular disease, renal insufficiency, blind-
ness, amputations) were excluded. Furthermore, subjects
were excluded if they had glaucoma [14] and if they were
using warfarin [15] because of possible adverse effects of
paroxetine in these conditions. Patients who used any
kind of antidepressants were excluded.
22 subjects were interviewed in person and 7 of these did
not meet the inclusion criteria for the study. Therefore, 15
subjects were randomly assigned to take either placebo (n
= 8) or 20 mg paroxetine (n = 7) once a day in a single-
blind fashion. The randomisation was computerised and
concealed to both patient, investigators, and treating phy-
sicians until inclusion and informed consent was estab-
lished. The allocation remained concealed to the patient,
treating physician and laboratory staff throughout the
trial. The investigator did not take part in the clinical treat-
ment of the study subjects.
At baseline and after 10 weeks the mental status of the
participants was evaluated using MADRS, BDI, RAND-36,
and HAM-A. At the same timepoints blood samples were
drawn for the following analyses: blood glucose, GHbA1c,
serum cholesterol, serum HDL-cholesterol, serum triglyc-
erides, free fatty acids (FFA), serum cortisol, sex hormone
binding globulin (SHBG), and serum leptin. LDL choles-
terol was calculated using the Friedewald formula. Body
mass index (kg/m2) was calculated using body weight
measured to the nearest 0,5 kg and height to the nearest
cm. Basal metabolic rate (kcal/24 h) was measured using
indirect calorimetry [16]. All measurements were made
after an overnight fast (at least 8 h fasting).
At baseline, at four week intervals, and at endpoint
adverse events were registered and the following safety
blood tests were taken: blood count, serum sodium,
serum potassium and liver enzymes. Subjects were to be
removed from the study if any safety tests showedBMC Family Practice 2003, 4 http://www.biomedcentral.com/1471-2296/4/7
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abnormal results. Compliance with the medication was
ensured by pill counting.
The primary outcome measures were global improve-
ment, defined as at least 20% increase in the total score of
quality of life, and metabolic improvement, defined as a
decrease in GHbA1c of at least 10%.
The study was approved by the Ethics Committee of Hel-
sinki University Central Hospital. All participants signed
an informed consent form.
Subjects who dropped out of the trial after more than two
weeks of participation were included in the analysis by
last observation carried forward technique. All analyses
were made with the SPSS 11.0 software. Differences
between groups in mean changes from baseline were ana-
lysed with the non-parametric two-tailed Mann-Whitney
U-test.
Results
Fifteen women entered randomisation; seven were allo-
cated to paroxetine and eight to placebo. One patient
withdrew her consent before starting medication and one
dropped out due to gastroenteritis after one week in the
trial. Both were allocated to the placebo group. All others
completed the 10 week trial (Figure 1).
Baseline characteristics of those women who entered and
completed the study are given in Table 1. Baseline features
were similar in the two treatment groups. The subjects
were in general obese with a non-optimal glycemic con-
trol having mean fasting blood glucose above 8 mmol/l.
All patients were using oral antidiabetic drugs except for
one diet treated individual in the placebo group. Three of
the patients in the paroxetine group were using insulin
and oral antidiabetic medication combined, but none of
the controls. Depression and anxiety scores indicated
presence of psychiatric distress among all study
participants.
After ten weeks we found that the mean decrease of the
GHbA1c value in the paroxetine group was 0.44%-units
(Table 2). There was a trend towards a more beneficial
outcome in the paroxetine group, as GHbA1c in the pla-
cebo group decreased only 0.07%-units (U = 9.0, p =
0,08). Fasting blood glucose improved in both groups
(1.5 mmol/l in the paroxetine group and 0.8 mmol/l in
the control group, U = 18.5, p = 0.72). A beneficial change
was seen in SHBG values in the paroxetine group in con-
trary to a decrease of SHBG in the placebo-treated group.
In this respect the treatment groups differed significantly
from each other (U = 3.0, p = 0.01). Body weight and
body mass index decreased slightly in both of the groups,
as well as serum cholesterol and LDL cholesterol.
Improvement in overall quality of life as measured by
RAND-36 did not differ between groups (U = 18.0, p =
0.67) (Table 3). The paroxetine-treated women evidenced
a decrease of anxiety and depressive symptoms in the
investigator-rated scales, but a significant difference
between paroxetine- and placebo-treated participants was
not reached (HAM-A U = 10.5, p = 0,13; MADRS U = 13.0,
p = 0.25). All participants, irrespective of group alloca-
tion, improved according to the patient-rated depression
scale BDI (U = 20.0, p = 0.88), but there was a trend for
greater decrease in serum cortisol levels, a depression
marker, in the paroxetine group (U = 8.0, p = 0.06).
Seven of the 14 patients who initiated medication
reported mild adverse events; four in the paroxetine group
and three in the control group. The paroxetine-treated
patients reported chronic constipation (n = 1), sweating
(n = 1), decreased appetite (n = 1), and hand paresthesias
(n = 1). It is likely that the sweating, decreased appetite,
and paresthesias were related to the paroxetine treatment.
The participants in the placebo group reported sweating
(n = 1), nausea combined with headache (n = 1), and gas-
troenteritis (n = 1). Due to her symptoms, the patient with
gastroenteritis discontinued her participation in the trial.
Figure 1
Flow chart of trial participants.
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Discussion
This is to our knowledge the first study where the meta-
bolic and mental health effects of paroxetine have been
simultaneously assessed in mildly depressed individuals
with type 2 diabetes. Our study was unable to demon-
strate a statistically significant difference in glycemic con-
trol between paroxetine-treated and placebo-allocated
women, but there was a trend for better control in the par-
oxetine group. In addition, we found a significant
improvement in an indicator of insulin sensitivity, SHBG,
in the treatment group when compared to the control
group.
Table 1: Baseline characteristics of mildly depressed women with type 2 diabetes who completed the trial
Controls (n = 6) Paroxetine (n = 7)
Mean SD Mean SD
Age (years) 62.3 11.5 61.1 8.6
Body mass index (kg/m2) 30.1 6.3 31.6 3.0
Metabolic parameters
Fasting blood glucose (mmol/l) 8.4 1.3 8.9 2.8
HbA1c (%) 6.9 0.4 7.5 0.8
S-cholesterol (mmol/l) 5.5 1.4 5.8 1.0
HDL cholesterol (mmol/l) 1.6 0.4 1.4 0.2
LDL cholesterol (mmol/l) 3.0 1.2 3.7 0.9
S-triglycerides (mmol/l) 2.1 1.1 1.5 0.7
Free fatty acids (mmol/l) 0.9 0.4 1.0 0.2
Sex hormone binding globulin (nmol/l) 74.2 34.3 38.9 19.5
S-leptin (ng/ml) 32.2 14.9 22.9 15.2
S-cortisol (nmol/l) 460.2 130.0 550.7 120.7
Energy expenditure (kcal/d) 1516.7 167.7 1658.6 246.5
Mental status
Hamilton's Anxiety Scale 9.3 3.7 13.7 4.2
Montgomery-Åsberg's Depression Rating Scale 6.4 4.0 7.4 2.9
Beck's Depression Inventory 13.0 9.2 13.7 7.4
RAND-36 436.8 182.0 455.6 142.7
Table 2: Mean changes in metabolic parameters between baseline and endpoint in women treated with placebo or paroxetine
Placebo (n = 6) Paroxetine (n = 7) 95% confidence 
interval of difference 
between groups
p*
Mean SD Mean SD
Body weight (kg) -0.83 0.98 -0.71 2.29 -2.30 to 2.06 0.60
Body mass index (kg/m2) -0.31 0.38 -0.26 0.88 -0.88 to 0.79 0.51
Blood glucose (mmol/l) -0.78 0.58 -1.47 2.52 -1.65 to 3.03 0.72
HbA1c % -0.07 0.33 -0.44 0.37 -0.05 to 0.80 0.08
S-cholesterol (mmol/l) -0.37 0.72 -0.16 0.62 -1.05 to 0.63 0.47
HDL-cholesterol (mmol/l) -0.07 0.10 0.01 0.13 -0.22 to 0.07 0.28
LDL-cholesterol (mmol/l) -0.38 0.65 -0.31 0.51 -0.80 to 0.68 0.57
S-triglycerides (mmol/l) 0.16 0.28 0.31 0.77 -0.87 to 0.58 0.72
Free fatty acids (mmol/l) -0.13 0.48 -0.29 0.41 -0.40 to 0.71 0.56
Sex hormone binding globulin (nmol/l) -9.33 15.67 20.29 20.57 -51.81 to -7.43 0.01
S-leptin (ng/ml) -3.75 6.73 -3.54 5.99 -8.12 to 7.70 0.89
S-cortisol (nmol/l) 104.83 151.05 -42.29 133.73 -30.17 to 324.41 0.06
Energy expenditure (kcal/d) -33.33 157.69 28.57 177.05 -266.35 to 142.54 0.57
*Mann-Whitney U-testBMC Family Practice 2003, 4 http://www.biomedcentral.com/1471-2296/4/7
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The paroxetine-treated women showed improvements in
investigator-rated aspects of mental health, but again sta-
tistical superiority when compared with the control group
was not reached. In this short study no superiority of par-
oxetine regarding improvement in quality of life was
detected.
An improvement in GHbA1c was observed after only ten
weeks of treatment with paroxetine. The decrease in
GHbA1c was not as big as 10% which was our a priori def-
inition for a good primary outcome. However, the average
decrease of 0.44% – units (~6% improvement) can cer-
tainly be considered to be of importance. It is a well-
known fact that any improvement in glycemic control
reduces the risk for microvascular complications [17]. We
chose GHbA1c as the primary metabolic outcome meas-
ure because it is more reliable than the fasting glucose
value, as it reflects the glycemic control during a 8 – 12
weeks time period. Fasting glucose may incidentally vary
a lot more and may also be affected by duration of fasting
and an inclusion in the study effect cannot be excluded.
Fasting blood glucose improved in both study groups. The
mean absolute improvement was larger in the paroxetine
group but statistical superiority of paroxetine was not
reached. Thus, we cannot exclude the possibility that the
improvement in fasting glucose in the both groups was
primarily due to the inclusion in study effect.
The strength of the results increases knowing that all three
women – all in the paroxetine group – who used insulin
reported that they had lowered their daily doses of insulin
during the trial. It is however impossible to calculate the
significance of this fact because there were no insulin-
users in the control group.
A low SHBG concentration is considered a risk factor for
type 2 diabetes and a direct correlation between insulin
sensitivity and SHBG has previously been demonstrated
[18,19]. In other words, low levels of SHBG are indicative
of insulin resistance. In the paroxetine group a superior
increase in SHBG levels were observed. This increase in
SHBG could be interpreted as a marker of improved insu-
lin sensitivity, nicely fitting the finding of improved glyc-
emic control in the paroxetine group.
The main shortcoming of this pilot study is the small sam-
ple size which is reflected in the low statistical power and
precision of outcome measures. The short duration con-
stitutes another weakness of the study. A longer duration
would probably have strengthened the trends seen in this
study. It is possible that changes in quality of life of chron-
ically ill populations need a longer time span to develop
than the current trial.
The relatively good glycemic control at baseline (average
GHbA1c level only 7.5%) may not have been optimal for
a demonstration of the full effect of treatment. Another
potential weakness is that the study was not double-blind
which may have influenced the results of the mental state
scales that were assayed by interview i.e. the HAM-A and
the MADRS. The authors have initiated a longer double-
blind placebo-controlled randomised study to replicate
the preliminary promising findings of the current study.
Conclusions
Taken together, the results are encouraging and should be
verified by other studies with a bigger sample size and
longer period of treatment. If paroxetine has a beneficial
effect on glucose and insulin metabolism in type 2 diabet-
ics as well as on quality of life and mental wellbeing it
could well be considered a drug of choice when treating
type 2 diabetics for depression. An augmentation of
standard diabetes care with SSRIs may be sensible even in
depressed patients who do not fulfil routine psychiatric
criteria for initiation of antidepressant drug treatment.
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